The effect of SGLT2 inhibition on heart failure in patients with type 2 diabetes has been evaluated in several landmark clinical trials, including EMPA-REG (empagliflozin) [28], DELCARE-TIMI (dapagliflozin) [57••], CANVAS (canagliflozin) [30] and VERITAS CV (ertugliflozin; ERT) [58]. Here, SLC5A2 is linked to heart failure.